Tyra Biosciences annual ebitda
2020
2021
2022
2023
2024
2025
Tyra Biosciences EBITDA Growth & History (TYRA)
Tyra Biosciences's calculated EBITDA was −$132.2M for fiscal 2025.
View full Tyra Biosciences company overviewTyra Biosciences annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$132.2M | −$28.6M | — |
| 2024 | 2024-12-31 | −$103.7M | −$24.1M | — |
| 2023 | 2023-12-31 | −$79.6M | −$21.0M | — |
| 2022 | 2022-12-31 | −$58.6M | −$32.5M | — |
| 2021 | 2021-12-31 | −$26.1M | −$16.9M | — |
| 2020 | 2020-12-31 | −$9.3M | — | — |
Tyra Biosciences quarterly ebitda
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$48.9M | −$17.6M | — |
| Q1 2026 | 2026-03-31 | −$41.9M | −$10.2M | — |
| Q4 2025 | 2025-12-31 | −$36.4M | −$6.8M | — |
| Q3 2025 | 2025-09-30 | −$32.8M | −$4.3M | — |
| Q2 2025 | 2025-06-30 | −$31.3M | −$7.9M | — |
| Q1 2025 | 2025-03-31 | −$31.7M | −$9.5M | — |
| Q4 2024 | 2024-12-31 | −$29.6M | −$4.0M | — |
| Q3 2024 | 2024-09-30 | −$28.5M | −$4.6M | — |
| Q2 2024 | 2024-06-30 | −$23.4M | −$7.5M | — |
| Q1 2024 | 2024-03-31 | −$22.2M | −$7.9M | — |
| Q4 2023 | 2023-12-31 | −$25.5M | −$10.6M | — |
| Q3 2023 | 2023-09-30 | −$23.9M | −$10.3M | — |
| Q2 2023 | 2023-06-30 | −$15.9M | −$565,000 | — |
| Q1 2023 | 2023-03-31 | −$14.3M | $519,000 | — |
| Q4 2022 | 2022-12-31 | −$14.9M | −$5.1M | — |
| Q3 2022 | 2022-09-30 | −$13.6M | −$7.0M | — |
| Q2 2022 | 2022-06-30 | −$15.4M | −$9.9M | — |
| Q1 2022 | 2022-03-31 | −$14.8M | −$10.6M | — |
| Q4 2021 | 2021-12-31 | −$9.9M | — | — |
| Q3 2021 | 2021-09-30 | −$6.6M | −$20.3M | — |
| Q2 2021 | 2021-06-30 | −$5.5M | — | — |
| Q1 2021 | 2021-03-31 | −$4.2M | — | — |
| Q3 2020 | 2020-09-30 | $13.7M | — | — |
Tyra Biosciences ebitda trends
Over the last five fiscal years, Tyra Biosciences's ebitda decreased from −$9.3M to −$132.2M, a change of −$123.0M. The latest reported quarter, Q2 2026, shows −$48.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tyra Biosciences source filings ↗Community posts
Tyra prices $400 million financing to support drug development
Tyra Biosciences ($TYRA) priced an underwritten financing expected to raise approximately $400 million before fees and expenses. The transaction comprises 9,079,000 common shares at $22.03 each and pre-funded warrants covering another 9,078 ...
